Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

451
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
451
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

5.2K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Alpelisib for TEK- and PIK3CA-Related Venous Malformations: A Systematic Review.

The Australasian journal of dermatology·2026
Same author

Autonomy vs nonmaleficence: Working out an isotretinoin dilemma.

Journal of the American Academy of Dermatology·2026
Same author

Infection Without Borders.

Journal of paediatrics and child health·2026
Same author

Direct-to-consumer healthcare and its expanding role in the Australian healthcare system.

Internal medicine journal·2026
Same author

Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis.

Dermatology and therapy·2025
Same author

Targeted management of vascular anomalies.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Related Experiment Video

Updated: May 22, 2025

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.3K

Targeted Therapies for Slow-Flow Vascular Malformations.

Grace X Li1,2, Deshan F Sebaratnam1,2, James P Pham1,2

  • 1Faculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia.

The Australasian Journal of Dermatology
|March 17, 2025
PubMed
Summary
This summary is machine-generated.

Targeted therapies, initially developed for cancer, show promise for treating vascular malformations. This review focuses on therapies targeting the PI3K/AKT/mTOR pathway, driven by genetic variants.

Keywords:
capillary malformationslymphatic abnormalitiesprecision medicinevascular malformationsvenous malformations

More Related Videos

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
14:58

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations

Published on: October 20, 2017

9.6K
Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.3K

Related Experiment Videos

Last Updated: May 22, 2025

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.3K
Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
14:58

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations

Published on: October 20, 2017

9.6K
Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.3K

Area of Science:

  • Genetics and Molecular Biology
  • Oncology
  • Vascular Biology

Background:

  • Genetic sequencing identifies somatic variants in vascular malformation pathogenesis.
  • These variants are also implicated in cancer development.
  • Targeted therapies from oncology are being explored for vascular malformations.

Purpose of the Study:

  • To review current evidence on targeted therapies for slow-flow vascular malformations.
  • To focus on therapies targeting the PI3K/AKT/mTOR pathway.
  • To examine the role of gain-of-function variants in treatment strategies.

Main Methods:

  • Literature review of genetic sequencing and targeted therapy studies.
  • Analysis of evidence for PI3K/AKT/mTOR pathway inhibitors.
  • Focus on slow-flow vascular malformations.

Main Results:

  • Growing evidence supports targeted therapies for vascular malformations.
  • Gain-of-function variants in PI3K/AKT/mTOR pathway are key targets.
  • Oncology-derived therapies demonstrate efficacy in preclinical and clinical settings.

Conclusions:

  • Targeted therapies, particularly those inhibiting the PI3K/AKT/mTOR pathway, offer a promising treatment avenue for vascular malformations.
  • Understanding the genetic basis of these malformations is crucial for personalized treatment.
  • Repurposing cancer therapies holds significant potential for improving patient outcomes.